About VIVA BIOTECH Company

We operate a comprehensive structure-based drug discovery platform (based on revenue in 2017 and measured by synchrotron beam time), and have a number of world-leading technologies and an expansive business model that shares the potential to increase the value of clients' intellectual property rights. We provide world-leading structure-based drug discovery services for pre-clinical innovative drug development for biotech and pharmaceutical customers around the world. Our services cover a full range of clients' needs for early drug discovery, including expression and structure studies of target proteins, drug screening, lead compound optimization, and identification of clinical candidate compounds. Our patented core technology and our proprietary expertise enable us to effectively reduce the average time required for drug discovery, which has been widely recognized by our customers. As of December 31, 2018, we have provided drug discovery services to over 370 biotech and pharmaceutical customers around the world, covering more than 1,000 independent drug targets and delivering approximately 9,500 independent protein structures. Our mission is to be the cradle of innovative biotech companies around the world.